Literature DB >> 34111575

Association of Inherited Chromosomally Integrated Human Herpesvirus 6 with Neurologic Symptoms and Management after Allogeneic Hematopoietic Cell Transplantation.

Madeleine R Heldman1, Cassandra Job2, Joyce Maalouf2, Jessica Morris2, Hu Xie2, Chris Davis2, Terry Stevens-Ayers2, Meei-Li Huang3, Keith R Jerome3, Jesse R Fann4, Danielle M Zerr5, Michael Boeckh6, Joshua A Hill7.   

Abstract

Reactivation of human herpesvirus 6 (HHV-6) after allogeneic hematopoietic cell transplantation (HCT) is associated with neurologic complications, but the impact of donor and/or recipient inherited chromosomally integrated HHV-6 (iciHHV-6) on post-HCT central nervous system (CNS) symptoms and diagnostic and therapeutic interventions is not well understood. The aims of the present study were (1) to compare the cumulative incidence of CNS symptoms in the first 100 days following allogeneic HCT among patients with donor and/or recipient iciHHV-6 (iciHHV-6pos)with that of patients with neither donor nor recipient iciHHV-6 (iciHHV-6neg) and (2) to assess the role of HHV-6 detection in driving potentially unnecessary interventions in iciHHV-6pos patients. We performed a retrospective matched cohort study of 87 iciHHV-6pos and 174 iciHHV-6neg allogeneic HCT recipients. HHV-6 testing was performed at the discretion of healthcare providers, who were unaware of iciHHV-6 status. The cumulative incidence of CNS symptoms was similar in iciHHV-6pos (n = 37; 43%) and iciHHV-6neg HCT recipients (n = 81; 47%; P = .63). HHV-6 plasma testing was performed in similar proportions of iciHHV-6pos (n = 6; 7%) and iciHHV-6neg (9%) patients and was detected in all tested iciHHV-6pos HCTs and 2 (13%) iciHHV-6neg HCTs. This resulted in more frequent HHV-6-targeted antiviral therapy after iciHHV-6pos HCT (odds ratio, 12.8; 95% confidence interval, 1.5 to 108.2) with associated side effects. HHV-6 plasma detection in 2 iciHHV-6pos patients without active CNS symptoms prompted unnecessary lumbar punctures. The cumulative incidence of CNS symptoms was similar after allogeneic HCT involving recipients or donors with and without iciHHV-6. Misattribution of HHV-6 detection as infection after iciHHV-6pos HCT may lead to unnecessary interventions. Testing for iciHHV-6 may improve patient management.
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hematopoietic cell transplantation; Human herpesvirus 6; Immunocompromised; Inherited chromosomally integrated human herpesvirus 6

Mesh:

Year:  2021        PMID: 34111575      PMCID: PMC8403634          DOI: 10.1016/j.jtct.2021.05.029

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  25 in total

1.  Prevalence of chromosomally integrated human herpesvirus 6 in patients with human herpesvirus 6-central nervous system dysfunction.

Authors:  Joshua A Hill; Ruth Hall Sedlak; Danielle M Zerr; Meei-Li Huang; Cecilia Yeung; David Myerson; Keith R Jerome; Michael J Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-22       Impact factor: 5.742

2.  A population-based study of primary human herpesvirus 6 infection.

Authors:  Danielle M Zerr; Amalia S Meier; Stacy S Selke; Lisa M Frenkel; Meei-Li Huang; Anna Wald; Margaret P Rhoads; Long Nguy; Rena Bornemann; Rhoda Ashley Morrow; Lawrence Corey
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

3.  The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro.

Authors:  Jesse H Arbuckle; Maria M Medveczky; Janos Luka; Stephen H Hadley; Andrea Luegmayr; Dharam Ablashi; Troy C Lund; Jakub Tolar; Kenny De Meirleir; Jose G Montoya; Anthony L Komaroff; Peter F Ambros; Peter G Medveczky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

4.  RNA Sequencing of the In Vivo Human Herpesvirus 6B Transcriptome To Identify Targets for Clinical Assays Distinguishing between Latent and Active Infections.

Authors:  Joshua A Hill; Minako Ikoma; Danielle M Zerr; Ryan S Basom; Vikas Peddu; Meei-Li Huang; Ruth Hall Sedlak; Keith R Jerome; Michael Boeckh; Serge Barcy
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

5.  HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients.

Authors:  Danielle M Zerr; Jesse R Fann; David Breiger; Michael Boeckh; Amanda L Adler; Hu Xie; Colleen Delaney; Meei-Li Huang; Lawrence Corey; Wendy M Leisenring
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

Review 6.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

7.  Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance.

Authors:  Deborah Siegal; Anne Keller; Wei Xu; Sandeep Bhuta; Dong Hwan Kim; John Kuruvilla; Jeffrey H Lipton; Hans Messner; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-21       Impact factor: 5.742

Review 8.  Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.

Authors:  Joshua A Hill; Danielle M Zerr
Journal:  Curr Opin Virol       Date:  2014-10-04       Impact factor: 7.090

9.  Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.

Authors:  Joshua A Hill; Sophia Koo; Belisa B Guzman Suarez; Vincent T Ho; Corey Cutler; John Koreth; Philippe Armand; Edwin P Alyea; Lindsey R Baden; Joseph H Antin; Robert J Soiffer; Francisco M Marty
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-04       Impact factor: 5.742

Review 10.  Chromosomally integrated human herpesvirus 6: questions and answers.

Authors:  Philip E Pellett; Dharam V Ablashi; Peter F Ambros; Henri Agut; Mary T Caserta; Vincent Descamps; Louis Flamand; Agnès Gautheret-Dejean; Caroline B Hall; Rammurti T Kamble; Uwe Kuehl; Dirk Lassner; Irmeli Lautenschlager; Kristin S Loomis; Mario Luppi; Paolo Lusso; Peter G Medveczky; Jose G Montoya; Yasuko Mori; Masao Ogata; Joshua C Pritchett; Sylvie Rogez; Edward Seto; Katherine N Ward; Tetsushi Yoshikawa; Raymund R Razonable
Journal:  Rev Med Virol       Date:  2011-11-04       Impact factor: 6.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.